Intervention not reported
Adverse events ‐ hypotony · People undergoing trabeculectomy surgery with glaucoma
It is very uncertain whether the intervention changes adverse events ‐ hypotony (very low certainty).
1 finding from 1 review
Diarrhoea · All patients with a diagnosis of multiple myeloma
Bortezomib may leads to higher adverse Events: Diarrhoea compared with no bortezomib (low certainty).
3 findings from 1 review
OR 2.44 [1.74, 3.43]
8 studies · 3788 participants
Low
OR 6.24 [2.79, 13.98]
4 studies · 1670 participants
Moderate
OR 1.8 [1.22, 2.65]
4 studies · 2118 participants
Moderate
Maternal adverse events · pregnant women undergoing caesarean section
1 finding from 1 review
Adverse events Gross 2011 · Adult patients with active ulcerative colitis
Budesonide showed no clear difference in adverse events Gross 2011 compared with mesalamine (moderate certainty).
1 finding from 1 review
Non‐serious adverse events · farmworkers
It is very uncertain whether summary of findings table ‐ Antibiotics changes non‐serious adverse events compared with other antibiotics (very low certainty).
1 finding from 1 review
Non‐serious adverse events · farmworkers, soldiers, and people in endemic areas
It is very uncertain whether summary of findings table ‐ Antibiotics changes non‐serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events – pneumonia · adults after cardiopulmonary resuscitation
The intervention showed no clear difference in adverse events – pneumonia (low certainty).
1 finding from 1 review
All serious adverse events · adults with acute spontaneous intracerebral haemorrhage
Summary of findings table ‐ Antifibrinolytic drug(s) showed no clear difference in all serious adverse events compared with placebo/open control (high certainty).
1 finding from 1 review
All serious adverse events · adults with acute spontaneous intracerebral haemorrhage associated with antiplatelet drug use
Summary of findings table ‐ Platelet transfusion showed no clear difference in all serious adverse events compared with open control (moderate certainty).
1 finding from 1 review
All serious adverse events · adults with acute spontaneous intracerebral haemorrhage associated with anticoagulant drug use
It is very uncertain whether summary of findings table ‐ Prothrombin complex concentrates changes all serious adverse events compared with fresh frozen plasma (very low certainty).
1 finding from 1 review
RR 0.27 [0.02, 3.74]
1 study · 5 participants
Very low
All serious adverse events · adults with acute spontaneous intracerebral haemorrhage
It is very uncertain whether summary of findings table ‐ Recombinant activated factor VII changes all serious adverse events compared with placebo/open control (very low certainty).
1 finding from 1 review
Adverse events: hypotension · type 1 or type 2 diabetics
Blood pressure intervention/intensive blood pressure intervention may leads to higher adverse events—hypotension compared with placebo/standard blood pressure intervention (low certainty).
1 finding from 1 review
Adverse events: all grades · hospitalized, mechanically ventilated adults with confirmed SARS‐CoV‐2 infection
Early showed no clear difference in adverse events (any grade) compared with late tracheostomy (low certainty).
1 finding from 1 review
Adverse events: thromboses · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes adverse events: thromboses compared with oral steroids alone (very low certainty).
1 finding from 1 review
Adverse events or toxicity · people with sickle cell disease
1 finding from 1 review
Intervention not reported
Secondary ‐ Adverse events · Patients with acute uncomplicated diverticulitis
The intervention showed no clear difference in secondary ‐ Adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse eventsLast · people with degenerative knee disease (osteoarthritis including degenerative meniscal tears)
The intervention showed no clear difference in serious adverse eventsLast (low certainty).
1 finding from 1 review
Adverse events: all grades · hospitalised people with confirmed SARS‐CoV‐2 infection
1 finding from 1 review
All serious adverse events · children
Rotarix leads to lower all serious adverse events compared with placebo (high certainty).
3 findings from 1 review
RR 0.85 [0.76, 0.95]
9 studies · 77069 participants
High
RR 0.9 [0.77, 1.05]
10 studies · 7674 participants
High
RR 0.89 [0.72, 1.1]
12 studies · 18971 participants
High
All serious adverse events · children
RotaTeq showed no clear difference in all serious adverse events compared with placebo (high certainty).
3 findings from 1 review
RR 0.92 [0.84, 1.01]
5 studies · 70690 participants
High
RR 0.66 [0.14, 3.17]
2 studies · 4082 participants
Very low
RR 0.99 [0.72, 1.36]
4 studies · 7730 participants
Moderate